Insight Molecular Diagnostics Inc.
corporate_fare Company Profile
Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for IMDX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for IMDX spans 10-Q, 8-K, SCHEDULE 13D/A, 4.
Recent high-impact activity:
- iMDx Prices $15M Offering at $1.75, a Discount to Its $1.66 Close
- Cash-Strapped iMDx Launches Public Offering With Stock at 52-Week Low
- iMDx Q2 Loss Deepens, Cash Runway Tightens; FDA Dialogue Continues
- iMDx Q2 Loss Widens to $11.3M; FDA Seeks Additional Data on GraftAssureDx
- FDA Advances GraftAssureDx Review, Requests Additional Info as iMDx Nears Authorization
Financial Snapshot
Short Interest & Short Volume
5.06 days to coverFINRA reported short interest of 1,025,397 shares in IMDX as of the October 30, 2026 settlement, a 8.0% increase from the prior period — about 5.1 days to cover at its recent average daily volume. On November 20, 2026, 27.8% of IMDX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for IMDX, detected from its recent SEC filings · based on capital-structure filings through 2026-11-18.
Offering Terms Finalized in Prospectus · Net Proceeds and Use
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →